Fig. 8

Targeting RGCC combined with paclitaxel/carboplatin therapy in lung-specific metastasis mice model. A, B Lung specific metastatic 4T1/LM3 and MDA-MB-231/LM3 cells with silencing RGCC and control cells were treated with serial dilutions of paclitaxel and carboplatin. IC50 values (A) and cell viability (B) were determined by CCK8 assay (n = 3). C Mice treatment scheme. D Overall survival of mice injected with MDA-MB-231/LM3/shNC or MDA-MB-231/LM3/shRGCC under combined management with or without paclitaxel/carboplatin (n = 7 mice per group). E Representative pulmonary surface nodules, H&E images (n = 7 mice per group) in each group of mice (scale bars, 400 μm). F–H Plots of the body weight (F), ratio of liver/body weight (G), and spleen/body weight (H) of mice (n = 7–9 mice/group). (Data were presented as mean ± SD; ^**P < 0.01, ^**.^*P < 0.001, ns: no statistical difference)